US 2014/0235535 A1 · ENGINEERED POLYPEPTIDES HAVING ENHANCED DURATION OF ACTION WITH REDUCED IMMUNOGENICITY

Abstract

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Claims20

Dependent claims

An engineered polypeptide comprising:

an albumin binding domain polypeptide (ABD), and
a first peptide hormone domain (HD1) comprising an exendin sequence, an exendin analog sequence or an active fragment sequence thereof, wherein said ABD comprises at least 95% identity to SEQ ID NO:300,
with the proviso that X7 is not L, E or D;
or alternatively,
with the proviso that the amino acid sequence is not SEQ ID NO:679.

2 more elements

Dependencies are inferred from the claim text.

Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Life of this patent

Engineered polypeptides having enhanced duration of action with reduced immunogenicity

Life of this patent

Abstract

Claims20